Biogen Idec, Inc. (Massachusetts) Increases Revenue 7% to $1.3 Billion in the First Quarter

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.